Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | JAK1 | P23458 | 3/20 | 0.41 |
| ▸ | TYK2 | P29597 | 3/20 | 0.41 |
| ▸ | JAK3 | P52333 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22638029 | 0.88 | JAK2 (0.48) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL22648842 | 0.83 | JAK2 (0.45) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL29467010 | 0.83 | JAK2 (0.45) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL22638003 | 0.83 | JAK2 (0.45) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL30882751 | 0.77 | CSNK1A1 (0.34) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL23168749 | 0.76 | JAK2 (0.39) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL29467008 | 0.76 | JAK2 (0.39) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL22648913 | 0.76 | JAK2 (0.39) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL22686552 | 0.76 | JAK2 (0.39) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL22638007 | 0.75 | JAK2 (0.40) | JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114269734-A | JAK inhibitors | 维玛兰生物科学公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3966209-A1 | JAK INHIBITORS | Vimalan Biosciences, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11136329-B2 | JAK inhibitors | VIMALAN BIOSCIENCES, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136329-B2 | JAK inhibitors | VIMALAN BIOSCIENCES, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200369669-A1 | JAK INHIBITORS | VIMALAN BIOSCIENCES, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20200369669-A1 | JAK INHIBITORS | VIMALAN BIOSCIENCES, INC. | 2020-11-26 | — | — | US | disclosed |
| WO-2020227563-A1 | JAK INHIBITORS | VIMALAN BIOSCIENCES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020227563-A1 | JAK INHIBITORS | VIMALAN BIOSCIENCES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369669-A1 | JAK INHIBITORS | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885TYK2 8/4885 |
| US-11136329-B2 | JAK inhibitors | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885TYK2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.